- Home
- /
- News
- /
- Drug Trials
- /
- June 2013
Drug Trials News for June 2013
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase.
24 June, 2013
An international team led by scientists at The Scripps Research Institute (TSRI), the Howard Hughes Medical Institute and Albert Einstein College of Medicine of Yeshiva University has identified a highly promising new anti-tuberculosis compound that attacks the tuberculosis (TB) bacterium in two different ways.
18 June, 2013
Cancer Research Technology, the commercial arm of Cancer Research UK, the University of Manchester and AstraZeneca today announced two agreements to seek new cancer drugs.
17 June, 2013
Picato (ingenol mebutate) gel is a topical treatment licensed for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (AK) in adults, a type of skin damage caused by long-term sun, or UV exposure, that has the potential to progress to the non-melanoma skin cancer, squamous cell carcinoma (SCC).
10 June, 2013
A lack of clinical trials aimed specifically at younger breast cancer patients could be partly to blame for their poorer survival rates, according to a major new Cancer Research UK study published in the Journal of the National Cancer Institute.
03 June, 2013
Virttu Biologics Limited, a UK biotechnology company with expertise in the field of oncolytic viruses, is pleased to announce at ASCO that an on-going clinical study in the USA with its oncolytic virus, SEPREHVIR® (HSV1716), in children and young adults with non-CNS tumours has received permission from the regulatory authorities to enrol patients to receive intra-venous administration of the virus.
01 June, 2013